Search results
Psoriasis: Features That May Affect Biologic Rx Outcomes
Medscape· 6 days agoSeveral clinical characteristics were negatively associated with responses to biologics in a...
AbbVie's (ABBV) Skyrizi Gets FDA Nod for Ulcerative Colitis
Zacks via Yahoo Finance· 4 days agoThe studies also achieved a key secondary endpoint of endoscopic improvement. Skyrizi is already...
TREMFYA® (guselkumab) studies underscore its potential to be the only IL-23 inhibitor to offer both...
Morningstar· 3 days agoJohnson & Johnson (NYSE: JNJ) today announced positive topline results from the pivotal Phase 3 GRAVITI investigational study of TREMFYA® (guselkumab) subcutaneous (SC) induction therapy in ...
FDA Approves Skyrizi for Ulcerative Colitis
Medscape· 5 days agoThe approval is the fourth indication for the anti–interleukin 23 monoclonal antibody after approval for Crohn's disease, psoriatic arthritis, and plaque...
Did Teva Pharmaceutical Industries Limited (TEVA)’s “Pivot to Growth” Strategy Help It Get a...
Insider Monkey via Yahoo Finance· 1 day agoWe recently compiled a list of the 10 Best Robinhood Stocks Under $20. In this article, we are going...
Modus Advisors LLC Acquires 450 Shares of AbbVie Inc. (NYSE:ABBV)
ETF DAILY NEWS· 4 days agoModus Advisors LLC raised its holdings in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 2.0% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities ...
Buckingham Capital Management Inc. Sells 94 Shares of AbbVie Inc. (NYSE:ABBV)
ETF DAILY NEWS· 10 hours agoBuckingham Capital Management Inc. cut its holdings in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 7.1% during the 1st quarter, Holdings Channel.com reports. The institutional investor ...
1,533 Shares in AbbVie Inc. (NYSE:ABBV) Acquired by Warren Street Wealth Advisors LLC
ETF DAILY NEWS· 5 days agoWarren Street Wealth Advisors LLC acquired a new position in AbbVie Inc. (NYSE:ABBV – Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange ...
In a 'gold rush' for treating bowel disease, AbbVie clears one more stage
Crain s Chicago Business· 4 days agoWith the arrival of biosimilar competition for its blockbuster drug Humira, AbbVie has said much of its sales growth potential lies with these two anti-inflammatories. In April, the North Chicago ...
M&R Capital Management Inc. Has $2.84 Million Holdings in AbbVie Inc. (NYSE:ABBV)
ETF DAILY NEWS· 4 days agoM&R Capital Management Inc. reduced its position in AbbVie Inc. (NYSE:ABBV – Free Report) by 0.6% during the 1st quarter, according to the company in its most recent filing with the Securities ...